The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study
Open accessAbstract
Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) when proteinuria is persistently ≥1 g/d despite 3-6 months of supportive care and when eGFR is >50 ml/min per 1.73 m(2). Whether the benefits of this treatment extend to patients with an eGFR≤50 ml/min per 1.73 m(2), other levels of proteinuria, or different renal pathologic lesions remains unknown. We retrospectively studied 1147 patients with IgAN from the European Validation Study of the Oxford Classification of IgAN (VALIGA) cohort classified according to the Oxford-MEST classification and medication used, with details of duration but not dosing. Overall, 46% of patients received immunosuppression, of which 98% received CS. Treated individuals presented with greater clinical and pathologic risk factors of progression. They also received more antihypertensive medication, and a greater proportion received renin angiotensin system blockade (RASB) compared with individuals without immunosuppressive therapy. Immunosuppression was associated with a significant reduction in proteinuria, a slower rate of renal function decline, and greater renal survival. Using a propensity score, we matched 184 subjects who received CS and RASB to 184 patients with a similar risk profile of progression who received only RASB. Within this group, CS reduced proteinuria and the rate of renal function decline and increased renal survival. These benefits extended to those with an eGFR≤50 ml/min per 1.73 m(2), and the benefits increased proportionally with the level of proteinuria. Thus, CS reduced the risk of progression regardless of initial eGFR and in direct proportion to the extent of proteinuria in this cohort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Cited by
Intensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Rodrigues, J. C., Haas, M., & Reich, H. N. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07420716 · Cited by 555
Lv, J., Zhang, H., Wong, M. G., Jardine, M. J., Hladunewich, M., Jha, V., Monaghan, H., Zhao, M., Barbour, S., Reich, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.9362 · Cited by 540
Self-citationLai, K. N., Tang, S. C. W., Schena, F. P., Novak, J., Tomino, Y., Fogo, A. B., & Glassock, R. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.1 · Cited by 508
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
Thompson, A., Carroll, K., A. Inker, L., Floege, J., Perkovic, V., Boyer-Suavet, S., W. Major, R., I. Schimpf, J., Barratt, J., Cattran, D. C., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08600718 · Cited by 317
Self-citation
Metadata
- Authors
- Tesar, V., Troyanov, S., Bellur, S., Verhave, J. C., Cook, H. T., Feehally, J., Roberts, I. S. D., Cattran, D., & Coppo, R.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2015-09
- Volume
- 26
- Issue
- 9
- Pages
- 2248-2258
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2110648558
- Cited by
- 217
- References
- 1
- FWCI
- 22.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. https://app.cochat.ai/papers/10.1681/asn.2014070697
- The paper
- Tesar, V., Troyanov, S., Bellur, S., Verhave, J. C., Cook, H. T., Feehally, J., Roberts, I. S. D., Cattran, D., & Coppo, R. (2015). Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2014070697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.